Senseonics Holdings, Inc. Common Stock Q2 Earnings Call Highlights

Senseonics Holdings, Inc. Common Stock NASDAQ: SENS raised its full-year 2026 revenue and gross-margin outlook after reporting second-quarter revenue growth of approximately 120% and its highest organic gross margin to date.

MarketBeat • Aug 7, 2026

Senseonics Holdings, Inc. (SENS) Q2 2026 Earnings Call Transcript

Senseonics Holdings, Inc. (SENS) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 7, 2026

Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates

Senseonics Holdings (SENS) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.4 per share a year ago.

Zacks Investment Research • Aug 6, 2026

Senseonics Holdings, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call for August 6, 2026 at 4:30 P.M. Eastern Time

GERMANTOWN, Md., July 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, August 6, 2026.

GlobeNewsWire • Jul 21, 2026

Strength Seen in Senseonics (SENS): Can Its 6.1% Jump Turn into More Strength?

Senseonics (SENS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research • Jun 29, 2026

Senseonics Expands Eversense 365 Ecosystem With Welldoc Partnership

SENS partners with Welldoc on a next-gen Eversense 365 app, adding Apple Health/Google Health Connect integration ahead of the U.S. launch.

Zacks Investment Research • Jun 11, 2026

Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026

GERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today highlights two key company events during the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5-8 in New Orleans, Louisiana.

GlobeNewsWire • Jun 1, 2026

Senseonics Holdings, Inc. Common Stock Q1 Earnings Call Highlights

Senseonics Holdings, Inc. Common Stock NASDAQ: SENS raised its full-year 2026 revenue outlook after reporting first-quarter growth tied to adoption of its Eversense 365 continuous glucose monitoring system and the integration of its U.S. commercial organization.

MarketBeat • May 9, 2026

Senseonics Holdings, Inc. (SENS) Q1 2026 Earnings Call Transcript

Senseonics Holdings, Inc. (SENS) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026

Senseonics Holdings, Inc. Reports First Quarter 2026 Financial Results

Generated Q1 revenue of $11.7 million, an increase of 87% year-over-year Expect full-year revenue in the range of $60M - $64M (previously $58M to $62M) Strong strategic and commercial progress, including the launch of Eversense® 365 in Europe Raised $100M+ in equity and debt financing to support commercial strategy and pipeline GERMANTOWN, MD., May 07, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced first quarter 2026 financial results and provided a business update.

GlobeNewsWire • May 7, 2026